Production of in situ crosslinkable polyisobutylene-polyurethane nanofibers and coatings
The complexity of polyisobutylene-polyurethane block copolymer manufacturing and deposition processing is solved by polymerization and deposition in the same solvent system and forming urea formate crosslinking during the deposition of polyisobutylene-polyurethane block copolymers. The quality and time-consuming problem enables more efficient polymer layer manufacturing.
Patent Information
- Application Number
- CN202411210870.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2015-10-17
- Filing Date
- 2016-10-14
- Publication Date
- 2024-12-06
AI Technical Summary
The manufacturing and solvent-based deposition processing of polyisobutylene-polyurethane block copolymers are complex and time-consuming, making it difficult to maintain the basic structure and properties of polymer materials.
Polymerization and deposition in the same solvent system, urea formate crosslinking is formed during the evaporation of the solvent system, simplifying the process from polymerization to deposition, reducing the drying step, and continuing polymerization after deposition to form more Strong and more durable polymer layer.
The entire process from polymerization to deposition is achieved in one day, improving the strength and durability of the polyisobutylene-polyurethane block copolymer and reducing manufacturing time and steps.
Smart Images

Figure CN119081064A_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application with an international application date of October 14, 2016, Chinese national application number of 201680060338.3, and invention name of "Production of in-situ cross-linkable polyisobutylene-polyurethane nanofibers and coatings".
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to Provisional Application No. 62 / 243,057, filed October 17, 2015, the entire contents of which are incorporated herein by reference. Technical Field
[0004] The present invention relates to medical devices and methods for making medical devices. More particularly, the present invention relates to methods for making medical devices and medical devices comprising a polyisobutylene-polyurethane block copolymer layer. Background Art
[0005] Polymer materials are widely used in the field of implantable medical devices. For example, polymer materials such as silicone rubber, polyurethane and fluoropolymers are used as coatings and / or insulating materials for medical leads, stents and other devices.
[0006] Incorporating polymeric materials into implantable medical devices can be done by a variety of methods, depending on the specific application. In some applications, for example, for an implantable lead body, the polymeric material can be extruded at a temperature sufficient to cause the polymeric material to flow but not high enough to cause the polymeric material to decompose. That is, the material that forms the lead after extrusion and cooling has substantially the same structure as the original polymeric material.
[0007] In other applications, it may be desirable to use solvent-based deposition methods to introduce polymeric material layers into implantable medical devices. Solvent-based deposition methods include electrospraying, electrospinning, spraying, dipping, and power spinning. It is important for all solvent-based deposition processes of polymeric materials that the polymeric material is in solution while maintaining the basic structure of the polymeric material. In some cases, the strength and chemical resistance characteristics that characterize certain polymeric materials also make it difficult to prepare the polymeric material and form a solution of the polymeric material.
[0008] Block copolymers are polymer materials made from alternating segments of polymerized monomers. Polyisobutylene-polyurethane block copolymers are polymer materials that possess many unique and desirable physical and mechanical properties, including thermal stability, chemical resistance, biocompatibility, and gas impermeability, among others. However, these physical properties can also make the manufacturing and solvent-based deposition processing of polyisobutylene-polyurethane block copolymers difficult and time consuming. Improvements in the manufacturing and solvent-based deposition processing of polyisobutylene-polyurethane block copolymers are needed. Summary of the invention
[0009] Embodiment 1 is a method for making a device comprising a polyisobutylene-polyurethane block copolymer. The method includes polymerizing a polyisobutylene diol, a diisocyanate, and a chain extender in a solvent system to form a polyisobutylene-polyurethane block copolymer solution, depositing the polyisobutylene-polyurethane block copolymer solution onto at least a portion of the device, and evaporating the solvent system from the deposited polyisobutylene-polyurethane block copolymer solution.
[0010] In embodiment 2, the method of embodiment 1, wherein the polymerization further comprises a polyether glycol in a solvent system to form a polyisobutylene-polyurethane block copolymer solution.
[0011] In Example 3, the method of Example 1 or 2, wherein evaporating the solvent system includes evaporating a first portion of the solvent system while depositing the polyisobutylene-polyurethane block copolymer solution, and evaporating a second portion of the solvent system after the deposited polyisobutylene-polyurethane block copolymer solution is deposited.
[0012] In Example 4, the method of Example 3 wherein allophanate crosslinks are formed within the polyisobutylene-polyurethane block copolymer during evaporation of the second portion of the solvent system.
[0013] In embodiment 5, the method of any of embodiments 1-4, wherein polymerization continues after deposition of the polyisobutylene-polyurethane block copolymer during evaporation of the solvent system.
[0014] In embodiment 6, the method of any one of embodiments 1-5, wherein the solvent system consists of one or more solvent components, and the one or more solvent components do not include hydroxyl, acid, acyl halide, primary amine, secondary amine, primary amide or secondary amide.
[0015] In embodiment 7, the method of any one of embodiments 1-6, wherein the solvent system comprises 2,6-lutidine.
[0016] In Example 8, the method of any one of Examples 1-7, wherein the solvent system comprises benzaldehyde and a solvent component selected from the group consisting of 1,3-dioxolane, 1,4-dioxane, triacetin, ethyl 3-ethoxypropionate, tetrahydrofuran, dimethyl sulfoxide, dibasic acid esters, tetramethylene sulfone and methyl phenyl acetate.
[0017] In Example 9, the method of any one of Examples 1-8, wherein the depositing comprises at least one of solvent casting, spraying, or dip coating the polyisobutylene-polyurethane block copolymer solution onto the device.
[0018] In embodiment 10, the method of any one of embodiments 1-8, wherein the solvent system comprises a solvent having a 0.5 The polar Hansen solubility parameter of at least about 4.4 MPa 0.5 or at least one solvent component having a hydrogen bonding Hansen solubility parameter of at least about 5.0 MPa 0.5 The solvent components have a polar Hansan solubility parameter of at least about 4.4 MPa 0.5 The hydrogen bonding Hansen solubility parameters of other solvent components.
[0019] In Example 11, the method of Example 10, wherein the depositing comprises at least one of electrospinning and electrospraying a polyisobutylene-polyurethane block copolymer solution onto the device.
[0020] In embodiment 12, the method of any of embodiments 1-11, wherein the Hansen solubility parameter distance relative energy difference between the polyisobutylene-polyurethane block copolymer and the solvent system is less than about 1.
[0021] In Example 13, a device comprising a polyisobutylene-polyurethane block copolymer and prepared according to the method of any one of Examples 1-12, wherein the copolymer comprises a plurality of linear polyisobutylene-polyurethane block copolymer segments; and a plurality of allophanate crosslinks between the linear polyisobutylene-polyurethane block copolymer segments.
[0022] In Example 14, the device of Example 13, wherein the copolymer is a thermosetting polymer.
[0023] In Example 15, the device of any one of Examples 13-14, wherein the device is an implantable medical device.
[0024] Embodiment 16 is a method for making an implantable medical device comprising a polyisobutylene-polyurethane block copolymer. The method comprises polymerizing a polyisobutylene diol, a diisocyanate, a chain extender, and optionally a polyether diol in a solvent system to form a polyisobutylene-polyurethane block copolymer solution, depositing the polyisobutylene-polyurethane block copolymer solution onto at least a portion of the implantable medical device, and evaporating the solvent system from the deposited polyisobutylene-polyurethane block copolymer solution.
[0025] In Example 17, the method of Example 16, wherein evaporating the solvent system comprises evaporating a first portion of the solvent system while depositing the polyisobutylene-polyurethane block copolymer solution, and evaporating a second portion of the solvent system after deposition of the deposited polyisobutylene-polyurethane block copolymer solution.
[0026] In Example 18, the method of Example 17, wherein allophanate crosslinks are formed within the polyisobutylene-polyurethane block copolymer during evaporation of the second portion of the solvent system.
[0027] In Example 19, the method of any of Examples 16-18, wherein polymerization continues after deposition of the polyisobutylene-polyurethane block copolymer during evaporation of the solvent system.
[0028] In Example 20, the method of any of Examples 16-19, wherein the solvent system consists of one or more solvent components, wherein the one or more solvent components have a boiling point below about 350°C, a relative evaporation rate greater than about 0.01, and a vapor pressure greater than about 0.5 mm Hg.
[0029] In embodiment 21, the method of any of embodiments 16-20, wherein the solvent system consists of one or more solvent components, and the one or more solvent components do not include hydroxyl, acid, acyl halide, primary amine, secondary amine, primary amide or secondary amide.
[0030] In embodiment 22, the method of any one of embodiments 16-21, wherein the solvent system comprises 2,6-lutidine.
[0031] In Example 23, the method of Example 22, wherein the solvent system consists of 2,6-lutidine.
[0032] In Example 24, the method of any one of Examples 16-21, wherein the solvent system comprises benzaldehyde and a solvent component selected from the group consisting of 1,3-dioxolane, 1,4-dioxane, triacetin, ethyl 3-ethoxypropionate, tetrahydrofuran, dimethyl sulfoxide, dibasic acid esters, tetramethylene sulfone and methyl phenyl acetate.
[0033] In Example 25, the method of any one of Examples 16-21, wherein the solvent system comprises benzaldehyde, 1,4-dioxane, and a solvent component selected from the group consisting of caprolactone (ε), dimethyl sulfoxide, tetramethylene sulfone, propylene carbonate, γ-butyrolactone, and N-methyl-2-pyrrolidone.
[0034] In embodiment 26, the method of any of embodiments 16-25, wherein polymerizing the polyisobutylene diol, diisocyanate, chain extender, and optional polyether diol in the solvent system comprises adding a tin catalyst to the solvent system.
[0035] In Example 27, the method of any of Examples 16-26, wherein the depositing comprises at least one of solvent casting, spraying, or dip coating the polyisobutylene-polyurethane block copolymer solution onto the implantable medical device.
[0036] In Example 28, the method of Examples 16-26, wherein the solvent system comprises a solvent having a 0.5 The polar Hansen solubility parameter of at least about 4.4 MPa 0.5 or at least one solvent component having a hydrogen bonding Hansen solubility parameter of at least about 5.0 MPa 0.5 The solvent components have a polar Hansan solubility parameter of at least about 4.4 MPa 0.5 The hydrogen bonding Hansen solubility parameters of other solvent components.
[0037] In Example 29, the method of Example 28, wherein the depositing comprises at least one of electrospinning and electrospraying a polyisobutylene-polyurethane block copolymer solution onto the implantable medical device.
[0038] In embodiment 30, the method of any of embodiments 16-29, wherein the diisocyanate is 4,4'-methylene diphenyl diisocyanate, the chain extender is 1,4-butanediol, and the optional polyether diol is polytetramethylene oxide diol.
[0039] In Example 31, the method of any of Examples 16-30, wherein the Hansen solubility parameter distance relative energy difference between the polyisobutylene-polyurethane block copolymer and the solvent system is less than about 1.
[0040] Embodiment 32 is an implantable medical device comprising a polyisobutylene-polyurethane block copolymer. The copolymer comprises a plurality of linear polyisobutylene-polyurethane block copolymer segments and a plurality of allophanate crosslinks between the linear polyisobutylene-polyurethane block copolymer segments.
[0041] In Example 33, the device of Example 32, wherein the copolymer is a thermosetting polymer.
[0042] In Example 34, the device of any of Examples 32 or 33, wherein the implantable medical device is a medical lead, and the polyisobutylene-polyurethane block copolymer is in the form of a plurality of electrospun fibers on a surface of the medical lead.
[0043] In Example 35, the device of Example 32 or 33, wherein the polyisobutylene-polyurethane block copolymer is in the form of a spray coating on at least a portion of the surface of the device.
[0044] Although multiple embodiments are disclosed, other embodiments of the present invention will become apparent to those skilled in the art based on the following detailed description which shows and describes exemplary embodiments of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 is a schematic diagram of an implantable medical device according to embodiment(s) of the present invention.
[0046] Figure 2A and 2B yes Figure 1 Schematic longitudinal cross-sectional view of a portion of an implantable medical device.
[0047] Figure 3 is a schematic diagram of electrospinning.
[0048] Figure 4 is an image of a thin polymer mesh of polyisobutylene-polyurethane block copolymer formed on an electrode coil of a lead according to an embodiment of the present invention.
[0049] Although the present invention is amenable to various modifications and alternative forms, specific embodiments have been illustrated by way of example in the accompanying drawings and described in detail below. However, it is not intended to limit the present invention to the specific embodiments described. On the contrary, the present invention is intended to cover all modifications, equivalents and substitutions falling within the scope of the present invention as defined by the appended claims. DETAILED DESCRIPTION
[0050] Historically, polyisobutylene-polyurethane block copolymers (PIB-PUR) can be made or polymerized in a first solvent, such as toluene, and then dried under vacuum or a nitrogen blanket to evaporate as much toluene from the PIB-PUR as possible. Once the first solvent evaporates, polymerization stops. Because PIB-PUR has excellent diffusion barrier properties, drying PIB-PUR may take several weeks. Once enough toluene is evaporated from the PIB-PUR, the PIB-PUR can be dissolved in a second solvent, such as pyridine, for deposition via a solvent-based deposition process. The PIB-PUR will not continue to polymerize in the second solvent. Because PIB-PUR has excellent chemical resistance, it may take additional days to turn the PIB-PUR into solution.
[0051] In an embodiment of the present invention, the polymerization to form the PIB-PUR and the subsequent solvent-based deposition process to deposit the PIB-PUR on the medical device are both performed using the same solvent system, as described below. Using the same solvent system from polymerization to deposition eliminates the need for a long processing step of drying the PIB-PUR and then turning it back into a solution for deposition by a solvent-based method. In an embodiment, the entire process from polymerization to deposition can be completed in one day.
[0052] Figure 1 Illustrative but non-limiting examples of medical applications using exemplary implantable medical devices are provided. The applications and locations are merely illustrative, as implantable medical devices incorporating embodiments of the present invention may be used in a variety of anatomical locations and for a variety of other purposes.
[0053] Figure 1 is a partial cross-sectional view of a medical electrical lead 10 according to various embodiments of the present disclosure. According to some embodiments, the medical electrical lead 10 may be configured for implantation in a patient's heart. According to other embodiments, the medical electrical lead 10 is configured for implantation in a neurovascular region of a patient. In yet another embodiment, the lead 10 may be a lead for a cochlear implant. The medical electrical lead 10 includes an elongated insulated lead body 12 extending from a proximal end 16 to a distal end 20. The proximal end 16 is configured to be operably connected to a pulse generator via a connector 24. At least one conductor 32 extends from the connector 24 at the proximal end 16 of the lead 10 to one or more electrodes 28 at the distal end 20 of the lead 10. The conductor 32 may be a coiled or cable conductor. According to some embodiments employing multiple conductors, the lead may include a combination of coiled and cable conductors. When a coiled conductor is used, according to some embodiments, the conductor may have a coradial or coaxial configuration.
[0054] Medical electrical lead 10 may be monopolar, bipolar, or multipolar, depending on the type of therapy to be delivered. In embodiments of the present disclosure employing multiple electrodes 28 and multiple conductors 32, each conductor 32 is adapted to be connected to a separate electrode 28 in a one-to-one manner, thereby allowing each electrode 28 to be individually accessed. Additionally, lead body 12 may include one or more lumens adapted to receive a guide element, such as a guide wire or stylet, for delivery of lead 10 to a target location within a patient's heart.
[0055] The electrode 28 can have any electrode configuration known in the art. According to one embodiment of the present disclosure, at least one electrode can be an annular or partially annular electrode. According to another embodiment, at least one electrode 28 is a shock coil. According to yet another embodiment of the present disclosure, at least one electrode 28 includes an exposed electrode portion and an insulated electrode portion. In some embodiments, a combination of electrode configurations can be used. The electrode 28 can be coated or formed with platinum, stainless steel, titanium, tantalum, palladium, MP35N, other similar conductive materials, any of the aforementioned alloys including platinum-iridium alloys, and other combinations of the aforementioned including coated metal layers or multiple metal materials.
[0056] Figure 2A and Figure 2B yes Figure 1 Schematic longitudinal cross-sectional view of the lead 10, wherein the internal structure has been removed for clarity. Figure 2A and 2B As shown, the lead 10 includes a PIB-PUR layer 40 disposed on various portions of the insulative lead body 12 . Figure 2A and 2B Illustrative but non-limiting examples of areas of lead 10 that may include PIB-PUR layer 40 are provided.
[0057] Figure 2A A PIB-PUR layer 40 is shown disposed on a portion of the insulated lead body 12. The illustrated portion of the insulated lead body 12 may be adjacent to an electrode, such as electrode 28, or may be spaced apart from the electrode. Figure 2B A PIB-PUR layer 40 is shown disposed on the electrode 28. Although the PIB-PUR layer 40 is shown as covering all of the electrode 28, in some embodiments, the PIB-PUR layer 40 covers only a small portion of the electrode 28, a large portion of the electrode 28, or an intervening portion of the electrode 28. Figure 2A and 2B In the embodiment shown, the PIB-PUR layer 40 may be porous to allow electrical contact between the electrode 28 and tissue at a target location within the patient's heart.
[0058] In an embodiment, polyisobutylene diol, diisocyanate, chain extender and optional polyether diol can be polymerized in a solvent system to form a PIB-PUR solution. In some embodiments, the polyisobutylene diol can be a telechelic polyisobutylene diol. The use of telechelic polyisobutylene diol produces multiple linear PIB-PUR segments. In some embodiments, the telechelic polyisobutylene diol can be saturated. Suitable diisocyanates may include 4,4'-methylenediphenyl diisocyanate (MDI), 2,4- and / or 2,6-toluene diisocyanate (TDI), 1,5-naphthalene diisocyanate (NDI), p-phenylene diisocyanate, 3,3'-tolidene-4,4'-diisocyanate, 3,3'-dimethyldiphenylmethane-4,4'-diisocyanate, 1,6-hexamethylene diisocyanate (HDI), 4,4'-dicyclohexylmethane diisocyanate, 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate (isophorone diisocyanate or IPDI), cyclohexyl diisocyanate, and 2,2,4-trimethyl-1,6-hexamethylene diisocyanate (TMDI). Suitable chain extenders may include ethylene glycol (1,2-ethylene glycol), 1,4-butanediol, and 1,6-hexanediol. Suitable optional polyether glycols may include polytetramethylene oxide glycol (PTMO glycol), polyhexamethylene oxide glycol (PHMO glycol), polyoctylene oxide glycol, and polydecamethylene oxide glycol. In some embodiments, polymerization may occur in the presence of a catalyst added to the solvent system. Suitable catalysts may include tin (II) 2-ethylhexanoate.
[0059] The solvent system according to the embodiment may include a single solvent component or multiple solvent components. Suitable solvent systems are capable of keeping PIB-PUR in solution, will not interfere with the polymerization process, and have sufficient volatility to evaporate from the PIB-PUR solution under conditions that will not damage the PIB-PUR. In addition, in order to be used for solvent-based deposition processes (such as electrospinning and electrospraying) that use electric fields to control the deposition of PIB-PUR solutions, suitable solvent systems may also have a polarity and hydrogen bonding level sufficient to support the interaction between the PIB-PUR solution and the electric field.
[0060] The solvent system according to the embodiment is capable of keeping PIB-PUR in solution. The Hansen Solubility Parameter (HSP) can be used to predict whether a material is soluble in another. The HSP consists of three parameters representing the forces acting between molecules of a substance: dispersion forces, polar intermolecular forces, and hydrogen bonding forces (see Charles M. Hansen, Hansen SolubilityParameters: AUser's Handbook(CRC Press, 2nd edition 2007). The three HSPs define a three-dimensional Hansen space. The three HSPs of a material are the coordinates of the Hansen space. Therefore, the HSPs of a material such as a single solvent component or a polymer determine the relative position of the material in Hansen space. The HSPs of a mixture of multiple solvent components are the volume-weighted combination of the HSPs of the individual solvent components that make up the mixture. Therefore, a mixture of multiple solvent components also has a relative position in Hansen space. The Hansen solubility parameter distance (Ra) is the distance between any two materials in Hansen space. Ra can be determined from the following equation 1:
[0061]
[0062] where δ d1 , δ p1 and δ h1 are the dispersed, polar, and hydrogen-bonded HSPs of one of the two materials, respectively; and δ d2 , δ p2 and δ h2 is the dispersion, polar and hydrogen bonding HSP of the other of the two materials. The HSP value for a particular solvent composition or polymer can be determined empirically or can also be found in published tables.
[0063] The interaction radius (R0) of the material to be dissolved can be determined. R0 is the distance in Hansen space at which any solvent component (or solvent mixture) may form a solution with the material. The ratio of Ra to R0 is called the relative energy difference (RED) and is a dimensionless number. For materials and solvent components (or multiple solvent components) with RED values greater than 1, the material and the solvent component may not be similar enough in their HSP to form a solution. Conversely, for materials and solvents (or multiple solvent components) with RED values less than 1, the material and the solvent component may be similar enough in their HSP that the material may form a solution with the solvent component. Therefore, RED can predict whether a material is likely to form a solution with a solvent component (or multiple solvent components).
[0064] In some embodiments of the present disclosure, the HSP and R0 of PIB-PUR have been determined empirically. For PIB-PUR, the dispersed HSP is about 19.3 MPa 0.5 , polar HSP is about 9.3MPa 0.5 , and the hydrogen bonding HSP is about 10.5MPa 0.5 The R0 of PIB-PUR is about 5.9. The HSP of various solvents can be found in, for example, Charles M. Hansen, HansenSolubility Parameters:AUser'sHandbook(CRC Press, 2nd ed., 2007), the entire contents of which are incorporated herein by reference.
[0065] In some embodiments, the solvent system may have a RED for PIB-PUR of less than about 1 to keep the PIB-PUR in solution. For example, a solvent system consisting of 2,6-lutidine has a dispersed HSP of about 19.0 MPa. 0.5 , polar HSP is about 8.9MPa 0.5 , and the hydrogen bonding HSP is about 5.4 MPa 0.5 Therefore, the solvent system of 2,6-lutidine has an Ra of about 5.2 and a RED of about 0.88 relative to PIB-PUR.
[0066] As described above, suitable solvent systems may not interfere with the polymerization process. That is, the solvent system is non-reactive to the polyisobutylene glycol, diisocyanate, chain extender, or optional polyether glycol. Therefore, the single solvent component or multiple solvent components of the solvent system do not include protogenic groups or any substances that will react with alcohols. In some embodiments, the single solvent component or multiple solvent components of the solvent system do not include hydroxyls, acids, acyl halides, primary amines, secondary amines, primary amides, or secondary amides. For example, a solvent system consisting of 2,6-lutidine does not include hydroxyls, acids, acyl halides, primary amines, secondary amines, primary amides, or secondary amides.
[0067] Suitable solvent systems also have sufficient volatility to evaporate from a PIB-PUR solution without damaging the PIB-PUR. One indicator of the volatility of a liquid is the relative evaporation rate (RER). As used herein, the RER is the evaporation rate of a liquid relative to the evaporation rate of n-butyl acetate, where the evaporation rate of n-butyl acetate is 100. In some embodiments, a single solvent component or multiple solvent components of a solvent system having an RER greater than about 0.01, greater than about 0.1, greater than about 1, or greater than any value between any of the foregoing values may have sufficient volatility to evaporate from a PIB-PUR solution.
[0068] Another indicator of the volatility of a liquid is its boiling point at 1 bar pressure. In some embodiments, a single solvent component or multiple solvent components of a solvent system having a boiling point below about 150° C., about 200° C., about 250° C., about 300° C., about 350° C., or any temperature below any of the foregoing temperatures may have sufficient volatility to evaporate from the PIB-PUR solution.
[0069] Another indicator of the volatility of a liquid is its vapor pressure. In some embodiments, a single solvent component or multiple solvent components of a solvent system having a vapor pressure greater than about 0.5 millimeters of mercury (mm Hg), greater than about 1 mm Hg, greater than about 2 mm Hg, greater than about 3 mm Hg, greater than about 5 mm Hg, or greater than about 10 mm Hg at 25° C., or greater than any vapor pressure between any of the foregoing vapor pressures, may have sufficient volatility to evaporate from the PIB-PUR solution.
[0070] In some embodiments, a single solvent component or multiple solvent components of the solvent system may have an RER greater than about 0.01, greater than about 0.1, greater than about 1, or greater than any value between any of the foregoing values; may have a boiling point less than about 150°C, about 200°C, about 250°C, about 300°C, about 350°C, or less than any temperature between any of the foregoing temperatures, and may have a vapor pressure greater than about 0.5 mm Hg, greater than about 1 mm Hg, greater than about 2 mm Hg, greater than about 3 mm Hg, greater than about 5 mm Hg, or greater than about 10 mm Hg, or greater than any vapor pressure between any of the foregoing vapor pressures. For example, a solvent system consisting of 2,6-lutidine has an RER of about 17, a boiling point of about 144°C at 1 bar, and a vapor pressure of 3.4 mm Hg at 25°C.
[0071] As described above, in embodiments where a solvent-based deposition process uses an electric field to control the deposition of the PIB-PUR solution (e.g., electrospinning and electrospraying), a suitable solvent system also has a polarity and hydrogen bonding level sufficient to support interaction between the PIB-PUR solution and the electric field. In such embodiments, a suitable solvent system may include a solvent having at least about 5.0 MPa 0.5 , about 5.6MPa 0.5 , about 6.2MPa 0.5 , about 6.8MPa 0.5 , or about 7.4MPa 0.5 The polar HSP of at least about 4.4 MPa 0.5 , about 4.6MPa 0.5 , about 4.8MPa 0.5 , about 5.0MPa 0.5 , or about 5.2MPa 0.5 In other embodiments, the solvent-based deposition process uses an electric field to control the deposition of the PIB-PUR solution. Suitable solvent systems may include a solvent having a viscosity of at least about 5.0 MPa. 0.5 , about 5.6MPa 0.5 , about 6.2MPa 0.5 , about 6.8MPa 0.5 , or about 7.4MPa 0.5At least one solvent component of a polar HSP and at least about 4.4 MPa 0.5 , about 4.6MPa 0.5 , about 4.8MPa 0.5 , about 5.0MPa 0.5 , or about 5.2MPa 0.5 At least one other solvent component having a hydrogen-bonded HSP. For example, a solvent system consisting of 2,6-lutidine has a polar HSP of about 8.9 MPa. 0.5 , and the hydrogen bonding HSP is about 5.4 MPa 0.5 .
[0072] In some embodiments, the solvent system can consist of a single solvent component. In some embodiments, the single solvent component can be selected from the group consisting of 2,6-dimethylpyridine benzaldehyde, 1,3-dioxolane, butyl benzoate, methyl phenylacetate, benzyl methyl ketone, ethyl cinnamate, 1,4-dioxane, cyclohexanone, propiophenone, ethyl phenylacetate, dichloromethane, benzyl ethyl ketone, tetrahydrofuran, isophorone, N-methyl-2-pyrrolidone, triacetin, phenylacetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide, dibasic acid esters and cyclopentyl methyl ether.
[0073] In other embodiments, the solvent system may include two solvent components, a first solvent component and a second component. In some embodiments, the first solvent component may be benzaldehyde, and the second solvent component may include one of 1,3-dioxolane, 1,4-dioxane, triacetin, 3-ethoxyethyl propionate, tetrahydrofuran, dimethyl sulfoxide, dibasic acid ester, tetramethylene sulfone and methyl phenylacetate. In other embodiments, the first solvent component may be 1,3-dioxolane, and the second solvent component may be one of caprolactone (ε), phenylacetonitrile and propylene carbonate. In yet another embodiment, the first solvent component may be 1,4-dioxane and the second solvent component may be caprolactone (ε). In some embodiments, the first solvent component may be present at a concentration greater than or equal to about 50% by weight, with the remainder being the second solvent component. In some embodiments, the weight ratio of the first solvent component to the second solvent component can be 50% / 50%, 60% / 40%, 70% / 30%, 80% / 20% or 90% / 10%, or 96% / 4%, or a weight ratio between any of the foregoing weight ratios.
[0074] In some other embodiments, the solvent system may include three solvent components, a first solvent component, a second component, and a third solvent component. In some embodiments, the first solvent component may be benzaldehyde, the second component may be 1,4-dioxane, and the third solvent component may be one of caprolactone (ε), dimethyl sulfoxide, tetramethylene sulfone, propylene carbonate, γ-butyrolactone, and N-methyl-2-pyrrolidone. In other embodiments, the first solvent component may be 1,4-dioxane, the second component may be caprolactone (ε), and the third solvent component may be one of aromatic hydrocarbons, toluene, ethylbenzene, butyl benzoate, phenylacetonitrile, and xylene. In some embodiments, the second solvent component may be present in an amount as little as about 20% by weight, about 25% by weight, or about 30% by weight, or may be present in an amount as much as about 35% by weight, about 40% by weight, or about 45% by weight, or between any pair of the aforementioned values. For example, in some embodiments, the second solvent component may be present in an amount of about 20% by weight to about 45% by weight, about 25% by weight to about 40% by weight, or about 30% by weight to about 35% by weight. In some embodiments, the third solvent component may be present in an amount as little as about 2 weight percent, about 5 weight percent, about 10 weight percent, or about 20 weight percent, with the balance being the first solvent component.
[0075] The PIB-PUR solution can be deposited on at least a portion of the medical electrical lead 10 by a solvent-based deposition process. In the solvent-based deposition process, the first part of the solvent system can evaporate in the deposition process of the PIB-PUR solution. Once the PIB-PUR solution is deposited, the second part of the solvent system will evaporate. Surprisingly, it is found that in the second part of the solvent system evaporation process, allophanate crosslinks (crosslinks) are formed in situ in the deposited PIB-PUR. Allophanate crosslinks are formed between linear PIB-PUR segments. The other structure provided by the allophanate crosslinks produces PIB-PUR, which can be stronger and more durable than the PIB-PUR manufactured and deposited by the previous method. For example, in some embodiments, due to the crosslinking of allophanate, the PIB-PUR of the resulting deposition can be a thermosetting polymer.
[0076] As described herein, PIB-PUR is maintained in the same solvent system from polymerization to deposition. That is, polyisobutylene glycol, diisocyanate, chain extender and optional polyether glycol are polymerized in the same solvent system of the PIB-PUR solution for deposition polymerization. Without wishing to be bound by any theory, it is believed that the continuous maintenance of PIB-PUR in solution from polymerization to deposition supports the sustained reactivity of the polymer chains in PIB-PUR. In addition, after the PIB-PUR solution is deposited, polymerization can be continued. When the second part of the solvent system evaporates, any polyisobutylene glycol, diisocyanate, chain extender and optional polyether glycol retained in the PIB-PUR solution become more concentrated, resulting in continuous polymerization. Additional polymerization can produce PIB-PUR, which can be stronger and more durable than PIB-PUR manufactured and deposited by historical methods, wherein polymerization ends with the evaporation of the solvent before the deposition process.
[0077] Figure 3 A schematic diagram of an exemplary solvent-based deposition process electrospinning is provided. An electric field may be used to draw a PIB-PUR solution 54 from a capillary source 52. The PIB-PUR solution 54 may be prepared as described above with reference to Figure 2A and 2B The capillary source 52 may be a syringe. The PIB-PUR solution 54 is drawn to a grounded collector 58. A high voltage power supply 56 may be used to power the process. Figure 1 , 2A 2B) to be coated element 60 can be placed on collector 58 to be coated. When PIB-PUR solution 54 is attracted to element 60 from capillary source 52 toward collector 58, the surface area of PIB-PUR increases significantly, causing the first part of the solvent system to evaporate from PIB-PUR solution 54 during deposition. Once deposited, as polymerization continues, the second part of the solvent system evaporates from PIB-PUR solution 54, and as described above, allophanate crosslinks are formed in the deposited PIB-PUR. When dry, a thin nanofiber polymer web 62 can be formed. In some embodiments, the nanofiber size can be controlled by adjusting the relative concentration of polymers in PIB-PUR solution 54.
[0078] Although the description herein discusses a PIB-PUR layer 40 deposited on a medical electrical lead 10, the PIB-PUR layer 40 can be deposited on any medical device, such as, but not limited to, an implantable electrical stimulation system or a diagnostic system, including a neurostimulation system such as a spinal cord stimulation (SCS) system, a deep brain stimulation (DBS) system, a peripheral nerve stimulation (PNS) system, a gastric nerve stimulation system, a cochlear implant system, and a retinal implant system, and the like, as well as a cardiac system, including an implantable cardiac rhythm management (CRM) system, an implantable cardioverter defibrillator (ICD), and a cardiac resynchronization and defibrillation (CRDT) device, and the like; and a catheter.
[0079] Example
[0080] The present invention will be described in more detail in the following examples, which are intended to be illustrative only, as many modifications and variations within the scope of the present invention will be apparent to those skilled in the art. Unless otherwise indicated, all parts, percentages and ratios reported in the following examples are by weight, and all reagents used in the examples are available or obtainable from the following chemical suppliers, or can be synthesized by conventional techniques.
[0081] Example 1
[0082] Polymerization of PIB-PUR in 2,6-dimethylpyridine
[0083] A mixture of 14.3 g of polyisobutylene diol (saturated, 88.8% polyisobutylene) and 6.82 g of polytetramethylene oxide diol was initially mixed with 50 g of toluene. The mixture was heated overnight at a temperature of 70° C. and under a nitrogen purge to remove moisture and toluene. The mixture was added to a 100 ml glass reactor along with 8.57 g of methylene diphenyl diisocyanate and 65 g of 2,6-lutidine. The mixture was stirred at 150 RPM and maintained at a temperature of 90° C. Agitation was provided by a rotating polytetrafluoroethylene paddle. After two hours, 0.02 g of tin (II) 2-ethylhexanoate was added to the reactor along with 3 ml of toluene. Five minutes later, 1.94 g of 1,4-butanediol and an additional 25 g of 2,6-lutidine were slowly added to the reactor to prevent the solution from becoming too viscous as the reactants polymerized in a solution containing 2,6-lutidine to form PIB-PUR. After one hour, the PIB-PUR solution is ready for the solvent-based deposition process.
[0084] Example 2
[0085] Deposition of PIB-PUR in 2,6-lutidine by electrospinning
[0086] A mixture of lithium bromide salt (LiBr) and the PIB-PUR solution prepared as described in Example 1 above were combined to form a solution containing 0.1 wt % LiBr. The PIB-PUR solution / salt mixture was loaded into a syringe and connected to the nozzle of an electrospinning machine. The PIB-PUR solution / salt mixture was electrospun onto an electrode coil of a medical electrical lead at a distance of 10 cm from the nozzle tip at a flow rate of 0.3 ml / hour to form a polymer mesh on the electrode coil. Environmental conditions included a relative humidity of 34% and a temperature of 23°C. Figure 4 This is an image of the prepared PIB-PUR thin polymer web at 1000 times magnification.
[0087] Example 3
[0088] Deposition of PIB-PUR in 2,6-lutidine by spray coating
[0089] A mixture of 69.795 g of the PIB-PUR solution prepared as described in Example 1 and an additional 75 ml of 2,6-lutidine was centrifuged at 5000 RPM for 20 minutes to dilute the PIB-PUR solution, reducing the viscosity from 0.354 Pa·s to 0.048 Pa·s. The PIB-PUR content was measured to be 26.6% before dilution and 15.2% after dilution. The diluted PIB-PUR solution was loaded into The 100% saturation cellulose was then applied to the braided inner coils used for medical electrical leads in a gravity air brush. The coils were set on a mandrel rotating at 350 RPM at room temperature and 60.2% relative humidity.
[0090] Various modifications and additions may be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the above embodiments refer to specific features, the scope of the present invention also includes embodiments with different combinations of features and embodiments that do not include all of the described features. Therefore, the scope of the present invention is intended to cover all such substitutions, modifications, and variations that fall within the scope of the claims, and all their equivalents.
Claims
1. A method for preparing a device comprising a polyisobutylene-polyurethane block copolymer, the method include: polymerizing polyisobutylene diol, diisocyanate and chain extender in a solvent system to form a polyisobutylene-polyurethane block copolymer solution; depositing a polyisobutylene-polyurethane block copolymer solution onto at least a portion of the device by electrospinning or electrospraying to form a nanofibrous polymer web; and evaporating the solvent system from the deposited polyisobutylene-polyurethane block copolymer solution; wherein polyisobutylene diol, diisocyanate and chain extender are polymerized in the same solvent system used to deposit the polyisobutylene-polyurethane block copolymer solution; wherein the solvent system consists of 2,6-lutidine; The relative energy difference of the Hansen solubility parameter distance between the polyisobutylene-polyurethane block copolymer and the solvent system is less than 1.
2. The method according to claim 1, wherein the evaporation solvent system include: evaporating a first portion of the solvent system while depositing the polyisobutylene-polyurethane block copolymer solution; and The second portion of the solvent system is evaporated after deposition of the deposited polyisobutylene-polyurethane block copolymer solution.
3. The method of claim 2, wherein during evaporation of the second portion of the solvent system, allophanate crosslinks are formed within the polyisobutylene-polyurethane block copolymer.
4. The method of claim 1, wherein polymerization continues after the polyisobutylene-polyurethane block copolymer is deposited during evaporation of the solvent system.
5. The method of claim 1, wherein depositing comprises at least one of solvent casting, spraying, or dip coating a polyisobutylene-polyurethane block copolymer solution onto the device.
6. The method of claim 1, further comprising adding a lithium bromide salt to the polyisobutylene-polyurethane block copolymer solution after the polymerizing step and before the depositing step.
7. The method of claim 1, wherein the diisocyanate is 4,4'-methylene diphenyl diisocyanate, the chain extender is 1,4-butanediol, and the polymerizing step further comprises polytetramethylene oxide diol.
8. A device comprising a polyisobutylene-polyurethane block copolymer and prepared according to the method of any one of claims 1 to 7, wherein the copolymer comprises: a plurality of linear polyisobutylene-polyurethane block copolymer segments; and Multiple allophanate crosslinks between the linear polyisobutylene-polyurethane block copolymer segments.
9. The device of claim 8, wherein the copolymer is a thermosetting polymer.
10. The device according to claim 8 or 9, wherein the device is an implantable medical device.
